173 related articles for article (PubMed ID: 32007210)
1. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Armstrong TS; Dirven L; Arons D; Bates A; Chang SM; Coens C; Espinasse C; Gilbert MR; Jenkinson D; Kluetz P; Mendoza T; Rubinstein L; Sul J; Weller M; Wen PY; van den Bent MJ; Taphoorn MJB
Lancet Oncol; 2020 Feb; 21(2):e97-e103. PubMed ID: 32007210
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.
Blakeley JO; Coons SJ; Corboy JR; Kline Leidy N; Mendoza TR; Wefel JS
Neuro Oncol; 2016 Mar; 18 Suppl 2(Suppl 2):ii13-ii20. PubMed ID: 26989128
[TBL] [Abstract][Full Text] [Related]
3. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
van den Bent MJ; Wefel JS; Schiff D; Taphoorn MJ; Jaeckle K; Junck L; Armstrong T; Choucair A; Waldman AD; Gorlia T; Chamberlain M; Baumert BG; Vogelbaum MA; Macdonald DR; Reardon DA; Wen PY; Chang SM; Jacobs AH
Lancet Oncol; 2011 Jun; 12(6):583-93. PubMed ID: 21474379
[TBL] [Abstract][Full Text] [Related]
4. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
Fangusaro J; Witt O; Hernáiz Driever P; Bag AK; de Blank P; Kadom N; Kilburn L; Lober RM; Robison NJ; Fisher MJ; Packer RJ; Young Poussaint T; Papusha L; Avula S; Brandes AA; Bouffet E; Bowers D; Artemov A; Chintagumpala M; Zurakowski D; van den Bent M; Bison B; Yeom KW; Taal W; Warren KE
Lancet Oncol; 2020 Jun; 21(6):e305-e316. PubMed ID: 32502457
[TBL] [Abstract][Full Text] [Related]
5. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
Sharma M; Juthani RG; Vogelbaum MA
Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
[TBL] [Abstract][Full Text] [Related]
6. Updates from the 2013 Society for Neuro-Oncology annual and World Federation for Neuro-Oncology quadrennial meeting.
Lukas RV; Amidei C
Tumori; 2014; 100(3):358-62. PubMed ID: 25076251
[TBL] [Abstract][Full Text] [Related]
7. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
[TBL] [Abstract][Full Text] [Related]
8. Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.
Dirven L; Armstrong TS; Blakeley JO; Brown PD; Grant R; Jalali R; Leeper H; Mendoza T; Nayak L; Reijneveld JC; Rhun EL; Walbert T; Weller M; Wen PY; Taphoorn MJB
Lancet Oncol; 2018 Mar; 19(3):e173-e180. PubMed ID: 29508764
[TBL] [Abstract][Full Text] [Related]
9. Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study.
Vera E; Christ A; Grajkowska E; Briceno N; Choi A; Crandon SK; Wall K; Lindsley M; Leeper HE; Levine J; Reyes J; Acquaye AA; King AL; Jammula V; Roche K; Rogers JL; Timmer M; Boris L; Lollo N; Panzer M; Polskin L; Pillai T; Burton E; Penas-Prado M; Theeler B; Gilbert MR; Armstrong TS; Mendoza TR
EClinicalMedicine; 2023 Jan; 55():101718. PubMed ID: 36386035
[TBL] [Abstract][Full Text] [Related]
10. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
[TBL] [Abstract][Full Text] [Related]
11. eHealth System for Collecting and Utilizing Patient Reported Outcome Measures for Personalized Treatment and Care (PROMPT-Care) Among Cancer Patients: Mixed Methods Approach to Evaluate Feasibility and Acceptability.
Girgis A; Durcinoska I; Levesque JV; Gerges M; Sandell T; Arnold A; Delaney GP;
J Med Internet Res; 2017 Oct; 19(10):e330. PubMed ID: 28970188
[TBL] [Abstract][Full Text] [Related]
12. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive approach in high-grade glioma management: position statement from the Neuro-Oncology Scientific Club (NOSC), Shiraz, Iran.
Ansari M; Mosalaei A; Ahmadloo N; Rasekhi A; Geramizadeh B; Razmkon A; Anvari K; Afarid M; Dadras A; Nafarieh L; Mohammadianpanah M; Nasrolahi H; Hamedi SH; Omidvari S; Nami M
Ger Med Sci; 2017; 15():Doc05. PubMed ID: 28325997
[TBL] [Abstract][Full Text] [Related]
14. Neuroradiological response criteria for high-grade gliomas.
Lutz K; Radbruch A; Wiestler B; Bäumer P; Wick W; Bendszus M
Clin Neuroradiol; 2011 Nov; 21(4):199-205. PubMed ID: 21681688
[TBL] [Abstract][Full Text] [Related]
15. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
16. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).
Helfer JL; Wen PY; Blakeley J; Gilbert MR; Armstrong TS
Neuro Oncol; 2016 Mar; 18 Suppl 2(Suppl 2):ii26-ii36. PubMed ID: 26989130
[TBL] [Abstract][Full Text] [Related]
17. Endpoints for clinical trials and revised assessment in neuro-oncology.
Butowski N; Chang SM
Curr Opin Neurol; 2012 Dec; 25(6):780-5. PubMed ID: 23007010
[TBL] [Abstract][Full Text] [Related]
18. The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature.
Turner-Bowker DM; Hao Y; Foley C; Galipeau N; Mazar I; Krohe M; Globe D; Shields AL
Curr Med Res Opin; 2016 Oct; 32(10):1709-17. PubMed ID: 27331272
[TBL] [Abstract][Full Text] [Related]
19. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
20. Evolving management of low grade glioma: No consensus amongst treating clinicians.
Field KM; Rosenthal MA; Khasraw M; Sawkins K; Nowak AK
J Clin Neurosci; 2016 Jan; 23():81-87. PubMed ID: 26601811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
